Additive effect of the mutations in the β3-adrenoceptor gene and UCP3 gene promoter on body fat distribution and glycemic control after weight reduction in overweight subjects with CAD or metabolic syndrome

O. Y. Kim, E. Y. Cho, H. Y. Park, Y. Jang, J. H. Lee

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

OBJECTIVE: To analyze the effects of the mutations in the β3-adrenoceptor (β3-AR) gene and/or uncoupling protein3 (UCP3) gene promoter on body fat distribution and glycemic control after mild weight reduction in overweight-obese subjects with coronary artery disease (CAD) or metabolic syndrome. DESIGN: Clinical intervention study of the -300 kcal/day mild weight reduction program for 12 weeks. SUBJECTS: A total of 224 overweight-obese subjects with CAD or metabolic disorder, subdivided into the following four categories: (1) wild type (TT-CC, n = 73); (2) only UCP3 promoter variant (TT-CT/TT, n = 90); (3) only β3-AR variant (TA/AA-CC, n = 29); (4) both variants (TA/AA-CT/TT, n = 32). MEASUREMENT: Body mass index (BMI), blood pressure, calorie intakes, body fat distribution, serum glucose, insulin, free fatty acids, C-peptide and lipids before and after weight reduction. RESULTS: After 12 weeks, all subjects lost approximately 5% of their initial body weight. Despite similar weight reduction, the highest decreases in abdominal adipose tissue at both L1 and L4 levels were observed in the 'wild-type' group (P < 0.001) and the second highest in 'only UPC3 promoter variant' group (P < 0.001). On the other hand, both variant-carriers had the smallest reduction only in visceral fat area at the L4 level. All subjects except both variant-carriers showed significant reductions in the fasting levels of glucose and FFA. The response areas of glucose (P < 0.01) and insulin (P < 0.05) were reduced largest in the 'wild-type' group and second largest in the 'UCP3 promoter variant' group. CONCLUSION: All the four groups showed similar weight reduction after -300 kcal/d for 12 weeks. However, the beneficial effects on body fat distribution and glycemic control were greatest in the 'wild-type' group and smallest in 'both variants' group. In addition, these effects were less beneficial in carriers with β3-AR gene variant than with UCP3 gene promoter variant.

Original languageEnglish
Pages (from-to)434-441
Number of pages8
JournalInternational Journal of Obesity
Volume28
Issue number3
DOIs
Publication statusPublished - 2004 Mar 1

Fingerprint

Body Fat Distribution
Adrenergic Receptors
Weight Loss
Coronary Artery Disease
Mutation
Glucose
Genes
Insulin
Weight Reduction Programs
Abdominal Fat
Intra-Abdominal Fat
C-Peptide
Nonesterified Fatty Acids
Fasting
Body Mass Index
Body Weight
Blood Pressure
Lipids
Serum

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics

Cite this

@article{3e403ad4e594431fb29d262414398044,
title = "Additive effect of the mutations in the β3-adrenoceptor gene and UCP3 gene promoter on body fat distribution and glycemic control after weight reduction in overweight subjects with CAD or metabolic syndrome",
abstract = "OBJECTIVE: To analyze the effects of the mutations in the β3-adrenoceptor (β3-AR) gene and/or uncoupling protein3 (UCP3) gene promoter on body fat distribution and glycemic control after mild weight reduction in overweight-obese subjects with coronary artery disease (CAD) or metabolic syndrome. DESIGN: Clinical intervention study of the -300 kcal/day mild weight reduction program for 12 weeks. SUBJECTS: A total of 224 overweight-obese subjects with CAD or metabolic disorder, subdivided into the following four categories: (1) wild type (TT-CC, n = 73); (2) only UCP3 promoter variant (TT-CT/TT, n = 90); (3) only β3-AR variant (TA/AA-CC, n = 29); (4) both variants (TA/AA-CT/TT, n = 32). MEASUREMENT: Body mass index (BMI), blood pressure, calorie intakes, body fat distribution, serum glucose, insulin, free fatty acids, C-peptide and lipids before and after weight reduction. RESULTS: After 12 weeks, all subjects lost approximately 5{\%} of their initial body weight. Despite similar weight reduction, the highest decreases in abdominal adipose tissue at both L1 and L4 levels were observed in the 'wild-type' group (P < 0.001) and the second highest in 'only UPC3 promoter variant' group (P < 0.001). On the other hand, both variant-carriers had the smallest reduction only in visceral fat area at the L4 level. All subjects except both variant-carriers showed significant reductions in the fasting levels of glucose and FFA. The response areas of glucose (P < 0.01) and insulin (P < 0.05) were reduced largest in the 'wild-type' group and second largest in the 'UCP3 promoter variant' group. CONCLUSION: All the four groups showed similar weight reduction after -300 kcal/d for 12 weeks. However, the beneficial effects on body fat distribution and glycemic control were greatest in the 'wild-type' group and smallest in 'both variants' group. In addition, these effects were less beneficial in carriers with β3-AR gene variant than with UCP3 gene promoter variant.",
author = "Kim, {O. Y.} and Cho, {E. Y.} and Park, {H. Y.} and Y. Jang and Lee, {J. H.}",
year = "2004",
month = "3",
day = "1",
doi = "10.1038/sj.ijo.0802562",
language = "English",
volume = "28",
pages = "434--441",
journal = "International Journal of Obesity",
issn = "0307-0565",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Additive effect of the mutations in the β3-adrenoceptor gene and UCP3 gene promoter on body fat distribution and glycemic control after weight reduction in overweight subjects with CAD or metabolic syndrome

AU - Kim, O. Y.

AU - Cho, E. Y.

AU - Park, H. Y.

AU - Jang, Y.

AU - Lee, J. H.

PY - 2004/3/1

Y1 - 2004/3/1

N2 - OBJECTIVE: To analyze the effects of the mutations in the β3-adrenoceptor (β3-AR) gene and/or uncoupling protein3 (UCP3) gene promoter on body fat distribution and glycemic control after mild weight reduction in overweight-obese subjects with coronary artery disease (CAD) or metabolic syndrome. DESIGN: Clinical intervention study of the -300 kcal/day mild weight reduction program for 12 weeks. SUBJECTS: A total of 224 overweight-obese subjects with CAD or metabolic disorder, subdivided into the following four categories: (1) wild type (TT-CC, n = 73); (2) only UCP3 promoter variant (TT-CT/TT, n = 90); (3) only β3-AR variant (TA/AA-CC, n = 29); (4) both variants (TA/AA-CT/TT, n = 32). MEASUREMENT: Body mass index (BMI), blood pressure, calorie intakes, body fat distribution, serum glucose, insulin, free fatty acids, C-peptide and lipids before and after weight reduction. RESULTS: After 12 weeks, all subjects lost approximately 5% of their initial body weight. Despite similar weight reduction, the highest decreases in abdominal adipose tissue at both L1 and L4 levels were observed in the 'wild-type' group (P < 0.001) and the second highest in 'only UPC3 promoter variant' group (P < 0.001). On the other hand, both variant-carriers had the smallest reduction only in visceral fat area at the L4 level. All subjects except both variant-carriers showed significant reductions in the fasting levels of glucose and FFA. The response areas of glucose (P < 0.01) and insulin (P < 0.05) were reduced largest in the 'wild-type' group and second largest in the 'UCP3 promoter variant' group. CONCLUSION: All the four groups showed similar weight reduction after -300 kcal/d for 12 weeks. However, the beneficial effects on body fat distribution and glycemic control were greatest in the 'wild-type' group and smallest in 'both variants' group. In addition, these effects were less beneficial in carriers with β3-AR gene variant than with UCP3 gene promoter variant.

AB - OBJECTIVE: To analyze the effects of the mutations in the β3-adrenoceptor (β3-AR) gene and/or uncoupling protein3 (UCP3) gene promoter on body fat distribution and glycemic control after mild weight reduction in overweight-obese subjects with coronary artery disease (CAD) or metabolic syndrome. DESIGN: Clinical intervention study of the -300 kcal/day mild weight reduction program for 12 weeks. SUBJECTS: A total of 224 overweight-obese subjects with CAD or metabolic disorder, subdivided into the following four categories: (1) wild type (TT-CC, n = 73); (2) only UCP3 promoter variant (TT-CT/TT, n = 90); (3) only β3-AR variant (TA/AA-CC, n = 29); (4) both variants (TA/AA-CT/TT, n = 32). MEASUREMENT: Body mass index (BMI), blood pressure, calorie intakes, body fat distribution, serum glucose, insulin, free fatty acids, C-peptide and lipids before and after weight reduction. RESULTS: After 12 weeks, all subjects lost approximately 5% of their initial body weight. Despite similar weight reduction, the highest decreases in abdominal adipose tissue at both L1 and L4 levels were observed in the 'wild-type' group (P < 0.001) and the second highest in 'only UPC3 promoter variant' group (P < 0.001). On the other hand, both variant-carriers had the smallest reduction only in visceral fat area at the L4 level. All subjects except both variant-carriers showed significant reductions in the fasting levels of glucose and FFA. The response areas of glucose (P < 0.01) and insulin (P < 0.05) were reduced largest in the 'wild-type' group and second largest in the 'UCP3 promoter variant' group. CONCLUSION: All the four groups showed similar weight reduction after -300 kcal/d for 12 weeks. However, the beneficial effects on body fat distribution and glycemic control were greatest in the 'wild-type' group and smallest in 'both variants' group. In addition, these effects were less beneficial in carriers with β3-AR gene variant than with UCP3 gene promoter variant.

UR - http://www.scopus.com/inward/record.url?scp=1542270110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542270110&partnerID=8YFLogxK

U2 - 10.1038/sj.ijo.0802562

DO - 10.1038/sj.ijo.0802562

M3 - Article

C2 - 14708035

AN - SCOPUS:1542270110

VL - 28

SP - 434

EP - 441

JO - International Journal of Obesity

JF - International Journal of Obesity

SN - 0307-0565

IS - 3

ER -